Nazarii Kobyliak1, Tetyana Falalyeyeva2, Galyna Mykhalchyshyn3, Dmytro Kyriienko4, Iuliia Komissarenko5. 1. Bogomolets National Medical University, T. Shevchenko boulevard, 13, Kyiv, 01601, Ukraine. Electronic address: nazariikobyliak@gmail.com. 2. Taras Shevchenko National University of Kyiv, Volodymyrska Str., 64/13, Kyiv, 01601, Ukraine. Electronic address: tfalalyeyeva@gmail.com. 3. Bogomolets National Medical University, T. Shevchenko boulevard, 13, Kyiv, 01601, Ukraine. Electronic address: gmykhalchyshyn@gmail.com. 4. Kyiv City Clinical Endocrinology Center, Pushkinska Str., 22a, Kyiv, 01601, Ukraine. Electronic address: kyriienkod@gmail.com. 5. Bogomolets National Medical University, T. Shevchenko boulevard, 13, Kyiv, 01601, Ukraine. Electronic address: julia.komissarenko@gmail.com.
Abstract
BACKGROUND:Probiotics have beneficial effect on obesity related disorders in animal models. Despite a large number of animal data, randomized placebo-controlled trials (RCT) concluded that probiotics have a moderate effect on glycemic control-related parameters. However, effect of probiotics on insulin resistance are inconsistent. AIM: In a double-blind single center RCT, effect of alive multistrain probiotic vs. placebo on insulin resistance in type 2 diabetes patient were assessed. METHODS: A total of 53 patients met the criteria for inclusion. They were randomly assigned to receive multiprobiotic "Symbiter" (concentrated biomass of 14 probiotic bacteria genera Bifidobacterium, Lactobacillus, Lactococcus, Propionibacterium) or placebo for 8-weeks administered as a sachet formulation. The primary main outcome was the change HOMA-IR (homeostasis model assessment-estimated insulin resistance) which calculated using Matthews et al.'s equation. Secondary outcomes were the changes in glycemic control-related parameters, anthropomorphic variables and cytokines. RESULTS: Supplementation with alive multiprobiotic for 8 weeks was associated with significant reduction of HOMA-IR from 6.85 ± 0.76 to 5.13 ± 0.49 (p = 0.047), but remained static in the placebo group. With respect to our secondary outcomes, HbA1c insignificant decreased by 0.09% (p = 0.383) and 0.24% (p = 0.068) respectively in placebo and probiotics groups. However, in probiotic responders (n = 22, patient with decrease in HOMA-IR) after supplementation a significant reduction in HbA1c by 0.39% (p = 0.022) as compared to non-responders was observed. In addition, from markers of chronic systemic inflammatory state only TNF-α and IL-1β changes significantly after treatment with probiotics. CONCLUSION:Probiotic therapies modestly improved insulin resistance in patients with type 2 diabetes.
RCT Entities:
BACKGROUND: Probiotics have beneficial effect on obesity related disorders in animal models. Despite a large number of animal data, randomized placebo-controlled trials (RCT) concluded that probiotics have a moderate effect on glycemic control-related parameters. However, effect of probiotics on insulin resistance are inconsistent. AIM: In a double-blind single center RCT, effect of alive multistrain probiotic vs. placebo on insulin resistance in type 2 diabetespatient were assessed. METHODS: A total of 53 patients met the criteria for inclusion. They were randomly assigned to receive multiprobiotic "Symbiter" (concentrated biomass of 14 probiotic bacteria genera Bifidobacterium, Lactobacillus, Lactococcus, Propionibacterium) or placebo for 8-weeks administered as a sachet formulation. The primary main outcome was the change HOMA-IR (homeostasis model assessment-estimated insulin resistance) which calculated using Matthews et al.'s equation. Secondary outcomes were the changes in glycemic control-related parameters, anthropomorphic variables and cytokines. RESULTS: Supplementation with alive multiprobiotic for 8 weeks was associated with significant reduction of HOMA-IR from 6.85 ± 0.76 to 5.13 ± 0.49 (p = 0.047), but remained static in the placebo group. With respect to our secondary outcomes, HbA1c insignificant decreased by 0.09% (p = 0.383) and 0.24% (p = 0.068) respectively in placebo and probiotics groups. However, in probiotic responders (n = 22, patient with decrease in HOMA-IR) after supplementation a significant reduction in HbA1c by 0.39% (p = 0.022) as compared to non-responders was observed. In addition, from markers of chronic systemic inflammatory state only TNF-α and IL-1β changes significantly after treatment with probiotics. CONCLUSION: Probiotic therapies modestly improved insulin resistance in patients with type 2 diabetes.
Authors: Judit Companys; Laura Pla-Pagà; Lorena Calderón-Pérez; Elisabet Llauradó; Rosa Solà; Anna Pedret; Rosa M Valls Journal: Adv Nutr Date: 2020-07-01 Impact factor: 8.701
Authors: Reyaz Hassan Mir; Goutami Godavari; Nasir Ali Siddiqui; Bilal Ahmad; Ramzi A Mothana; Riaz Ullah; Omer M Almarfadi; Sanjay M Jachak; Mubashir Hussain Masoodi Journal: Drug Des Devel Ther Date: 2021-02-04 Impact factor: 4.162